Replies to post #149968 on Biotech Values

[mcbio]

Are you referring to the marketcap or EV? From a EV point of view IDIX is about identical to that of medivir depending on how much cash IDIX has burnt since june.

Market cap. Not to discount EV by any means, but I place a higher priority on market cap myself.

What are the financial terms for Medivir's partnership with J&J? Thanks.

Unknown. To be safe, given that Medivir has never explicitly come out and said they would receive double-digit royalties, to the best of my knowledge, I am assuming single-digits. As long as they can at least earn high single-digit royalties, then I'm comfy with holding at this valuation. All this said, someone on Twitter (@BioKaiser) did state awhile ago that they are due double-digit royalties on the partnership but I cannot confirm that. (Don't know their source on that or how reliable that person is.)